Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2017

 Published On: Nov, 2017 |    No of Pages: 115 |  Published By: Global Markets Direct | Format: PDF
Request Free Sample

Summary

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 3, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal and Central Nervous System which include indications Hepatocellular Carcinoma, Solid Tumor, Type 2 Diabetes, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Ovarian Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Recurrent Glioblastoma Multiforme (GBM), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Chronic Lymphocytic Leukemia (CLL), Constipation, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Biliary Tract Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and itís most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview 8
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 14
Products under Development by Universities/Institutes 21
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment 23
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 29
Amgen Inc 29
ArQule Inc 29
AstraZeneca Plc 30
Blueprint Medicines Corp 30
Bristol-Myers Squibb Co 31
Eisai Co Ltd 31
Eli Lilly and Co 33
Genosco Inc 33
H3 Biomedicine Inc 34
Incyte Corp 34
Ionis Pharmaceuticals Inc 35
Johnson & Johnson 35
Merrimack Pharmaceuticals Inc 36
NGM Biopharmaceuticals Inc 36
Novartis AG 37
Principia Biopharma Inc 37
Tasly Pharmaceutical Group Co Ltd 38
Vichem Chemie Research Ltd 38
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles 40
ARQ-087 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
AZ-709 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
BLU-554 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
BLU-9931 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
BMS-986036 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
erdafitinib - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ES-135 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
FGF-401 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Fusion Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
golvatinib tartrate + lenvatinib mesylate - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
H-3B6527 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
INCB-62079 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
infigratinib - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
IONIS-463588 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
lenvatinib mesylate - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
LY-2874455 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
MM-161 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
NGM-282 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
PRN-1371 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
TSLB-1344 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products 93
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products 94
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones 95
Featured News & Press Releases 95
Oct 31, 2017: New Drug Application Of Anticancer Agent Lenvatinib For Hepatocellular Carcinoma Accepted In China 95
Oct 20, 2017: Bristol-Myers Squibb to Present New Data on its liver disease drug candidate BMS-986036 at The Liver Meeting 2017 95
Oct 19, 2017: NGM Bio Provides Update On NGM282 In NASH 96
Oct 10, 2017: H3 Biomedicine Granted Orphan Drug Designation of H3B-6527 for Treatment of Hepatocellular Carcinoma 98
Sep 29, 2017: Eisai Presents Results of Phase III Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting 98
Sep 27, 2017: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA 100
Sep 26, 2017: FDA Accepts Supplemental New Drug Application for Eisais Lenvatinib for the Treatment of Liver Cancer 101
Sep 19, 2017: Eisai Presents Results Of Phase III Clinical Study Of Lenvima (Lenvatinib) In Unresectable Hepatocellular Carcinoma At 11th ILCA Annual Conference 102
Sep 15, 2017: H3 Biomedicine to Present New Data on H3B-6527, an FGFR4 Inhibitor, at the 2017 International Liver Cancer Association Annual Meeting 103
Sep 11, 2017: Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress 104
Sep 11, 2017: Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima in Combination With Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress 105
Sep 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma 106
Sep 01, 2017: Eisai to Present 3 Abstracts on Lenvima at ESMO 2017 Congress 108
Sep 01, 2017: Eisai To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress 109
Aug 28, 2017: Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 11
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13
Number of Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 19
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 20
Number of Products under Investigation by Universities/Institutes, H2 2017 21
Products under Investigation by Universities/Institutes, H2 2017 22
Number of Products by Stage and Mechanism of Actions, H2 2017 24
Number of Products by Stage and Route of Administration, H2 2017 26
Number of Products by Stage and Molecule Type, H2 2017 28
Pipeline by Amgen Inc, H2 2017 29
Pipeline by ArQule Inc, H2 2017 30
Pipeline by AstraZeneca Plc, H2 2017 30
Pipeline by Blueprint Medicines Corp, H2 2017 31
Pipeline by Bristol-Myers Squibb Co, H2 2017 31
Pipeline by Eisai Co Ltd, H2 2017 32
Pipeline by Eli Lilly and Co, H2 2017 33
Pipeline by Genosco Inc, H2 2017 34
Pipeline by H3 Biomedicine Inc, H2 2017 34
Pipeline by Incyte Corp, H2 2017 35
Pipeline by Ionis Pharmaceuticals Inc, H2 2017 35
Pipeline by Johnson & Johnson, H2 2017 36
Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 36
Pipeline by NGM Biopharmaceuticals Inc, H2 2017 37
Pipeline by Novartis AG, H2 2017 37
Pipeline by Principia Biopharma Inc, H2 2017 38
Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 38
Pipeline by Vichem Chemie Research Ltd, H2 2017 39
Dormant Projects, H2 2017 93
Discontinued Products, H2 2017 94

List of Figures
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Top 10 Indications, H2 2017 11
Number of Products by Mechanism of Actions, H2 2017 23
Number of Products by Stage and Mechanism of Actions, H2 2017 23
Number of Products by Routes of Administration, H2 2017 25
Number of Products by Stage and Routes of Administration, H2 2017 25
Number of Products by Molecule Types, H2 2017 27
Number of Products by Stage and Molecule Types, H2 2017 27


If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.